Bayer AG (MEX:BAYN)
MXN 541.8 0 (0%) Market Cap: 520.56 Bil Enterprise Value: 1.11 Til PE Ratio: 0 PB Ratio: 0.87 GF Score: 59/100

Bayer AG at UBS Global Healthcare Conference (Virtual) Transcript

May 19, 2020 / 11:30AM GMT
Release Date Price: MXN1526
Michael Leuchten
UBS Investment Bank, Research Division - Co-Head of Pharmaceuticals Research of Equity Research

Good morning, good afternoon, everybody. My name is Michael Leuchten. I'm one of the pharma analysts at UBS based in London. It's my pleasure today to introduce the Bayer team for today's -- for today's fireside chat, we have Jörgen Möller who's -- so Jörg Möller who's the Head of R&D at Bayer pharma, and we also have Jürgen Beunink with us from the IR team.

For participants on today's presentation, there is a way of submitting questions to me. I will see them on my screen. If you want to do that, please do so. We will have a start off with a list of questions that I will go through with Jörg, and then we'll see how far we can go and we can maybe fill some questions after.

So with that, thank you very much for joining us today.

Questions & Answers

Michael Leuchten
UBS Investment Bank, Research Division - Co-Head of Pharmaceuticals Research of Equity Research

Maybe to start off with, obviously, the COVID

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot